KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Other Non Operating Income (2016 - 2026)

Abbott Laboratories' Other Non Operating Income history spans 18 years, with the latest figure at $13.0 million for Q1 2026.

  • On a quarterly basis, Other Non Operating Income fell 89.76% to $13.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $434.0 million, a 27.3% decrease, with the full-year FY2025 number at $548.0 million, up 45.74% from a year prior.
  • Other Non Operating Income hit $13.0 million in Q1 2026 for Abbott Laboratories, down from $134.0 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for ABT hit a ceiling of $496.0 million in Q4 2023 and a floor of -$19.0 million in Q3 2022.
  • Historically, Other Non Operating Income has averaged $131.9 million across 5 years, with a median of $124.0 million in 2024.
  • Biggest five-year swings in Other Non Operating Income: plummeted 300.0% in 2023 and later soared 1470.0% in 2025.
  • Tracing ABT's Other Non Operating Income over 5 years: stood at $337.0 million in 2022, then skyrocketed by 47.18% to $496.0 million in 2023, then fell by 27.62% to $359.0 million in 2024, then tumbled by 62.67% to $134.0 million in 2025, then tumbled by 90.3% to $13.0 million in 2026.
  • Business Quant data shows Other Non Operating Income for ABT at $13.0 million in Q1 2026, $134.0 million in Q4 2025, and $150.0 million in Q3 2025.